Bildkälla: Stockfoto

Active Biotech Q3 2023: Rights Issue Paves the Way for Phase II in Myelofibrosis - Redeye

Redeye comments on Active Biotech's Q3 report and the rights issue that was simultaneously announced.

Redeye comments on Active Biotech's Q3 report and the rights issue that was simultaneously announced.
Börsvärldens nyhetsbrev
ANNONSER